Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

Next Previous
X
Search
Trial Profile

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitazoxanide (Primary) ; Vitamin B complex
  • Indications COVID-19 respiratory infection
  • Focus Registrational; Therapeutic Use
  • Sponsors Romark Laboratories

    • Most Recent Events

    • 09 Mar 2022 According to a Romark Laboratories media release, results have been published in Lancet's eClinicalMedicine.
    • 09 Mar 2022 Results published in Romark Laboratories Media Release.
    • 14 Apr 2021 According to a Romark Laboratories media release, the company is working with FDA and plans to seek Emergency Use Authorization in the U.S.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top